Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.87 +5.7%	$2.35	$1.11 ▼ $13.91	$55.84M	1.57	389,183 shs	303,502 shs
APHB Ampliphi Biosciences	$2.22 -2.2%	$1.79	$0.15 ▼ $1.37	$74.30M	N/A	842,200 shs	3,697 shs
ONC BeOne Medicines	$252.14 +0.7%	$247.19	$146.21 ▼ $287.88	$27.63B	0.28	432,422 shs	105,997 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	+14.05%	-3.37%	+120.24%	-77.63%
APHB Ampliphi Biosciences	0.00%	+2.30%	+10.45%	+131.25%	-29.52%
ONC BeOne Medicines	0.00%	+1.96%	-7.17%	+3.11%	+25,029,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.5646 of 5 stars	3.5	1.0	0.0	0.0	0.6	1.7	0.6
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	3.4482 of 5 stars	4.5	0.0	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$18.00	528.27% Upside
APHB Ampliphi Biosciences	0.00	N/A	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$320.67	27.18% Upside

Current Analyst Ratings Breakdown

Latest ANVS, SCLP, APHB, REDX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/8/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/24/2025	ONC BeOne Medicines	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00
4/21/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$311.00 ➝ $317.00
4/16/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	$3.81B	7.25	N/A	N/A	$34.10 per share	7.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
APHB Ampliphi Biosciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	355.13	N/A	-9.40%	-7.55%	-4.42%	N/A

Latest ANVS, SCLP, APHB, REDX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
APHB Ampliphi Biosciences	N/A	N/A	N/A
ONC BeOne Medicines	0.05	1.96	1.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
APHB Ampliphi Biosciences	N/A
ONC BeOne Medicines	48.55%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
APHB Ampliphi Biosciences	N/A
ONC BeOne Medicines	6.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
APHB Ampliphi Biosciences	30	33.47 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A

ANVS, SCLP, APHB, REDX, and ONC Headlines

Recent News About These Companies

BeOne Medicines (NASDAQ:ONC) Rating Lowered to Hold at Wall Street Zen

July 14 at 2:01 AM | americanbankingnews.com

Biocytogen Enters into Antibody Licensing Agreement with BeOne ...

July 13 at 2:46 PM | businesswire.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 27,802 Shares

July 12 at 6:12 AM | insidertrades.com

BeOne Medicines (NASDAQ:ONC) Cut to Hold at Wall Street Zen

July 12 at 2:55 AM | marketbeat.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock

July 11 at 7:52 PM | marketbeat.com

BeOne Medicines Ltd. American Depositary Shares (ONC) Insider Activity

July 11 at 9:33 AM | nasdaq.com

Brokerages Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $320.67

July 11 at 2:15 AM | americanbankingnews.com

Biocytogen inks antibody deal with BeOne, expanding strategic ties

July 10, 2025 | thepharmaletter.comT

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

July 10, 2025 | ncnewsonline.comN

NICE moves fast on Brukinsa in MCL

July 10, 2025 | thepharmaletter.comT

European Commission Approves TEVIMBRAÂ® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

July 10, 2025 | businesswire.com

NICE backs new drugs for Crohn's disease, lymphoma

July 10, 2025 | pharmaphorum.comP

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

July 9, 2025 | businesswire.com

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

July 9, 2025 | businesswire.com

ONC BeOne Medicines Ltd. - Seeking Alpha

July 8, 2025 | seekingalpha.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of "Buy" from Brokerages

July 8, 2025 | marketbeat.com

This Startup Built A Hospital In India To Test Its AI Software

July 2, 2025 | forbes.com

BeOne Medicines showcases oncology pipeline

June 27, 2025 | thepharmaletter.comT

BeOne Medicines (NASDAQ:ONC) Shares Gap Down - Time to Sell?

June 27, 2025 | marketbeat.com

Morgan Stanley Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

June 27, 2025 | marketbeat.com

BeOne Medicines (NASDAQ:ONC) Price Target Raised to $321.00

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, SCLP, APHB, REDX, and ONC Company Descriptions

Annovis Bio NYSE:ANVS

$2.86 +0.16 (+5.72%)

Closing price 03:58 PM Eastern

Extended Trading

$2.86 0.00 (-0.03%)

As of 04:49 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Ampliphi Biosciences NYSEAMERICAN:APHB

$2.22 -0.05 (-2.20%)

As of 07/11/2025

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

BeOne Medicines NASDAQ:ONC

$252.14 +1.84 (+0.74%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time